This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Ghilardi, G. et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T- cell therapy. Nat. Med. https://doi.org/10.1038/s41591-024-02826-w (2024)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Papatriantafyllou, M. Low risk of CAR T cells going rogue. Nat Rev Immunol 24, 159 (2024). https://doi.org/10.1038/s41577-024-01007-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41577-024-01007-7